Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
In phase I: Establishing maximally tolerated dose of lenalidomide in combination with
bendamustine and rituximab.
In phase II: Evaluation of progression free survival with treatment with lenalidomide,
bendamustine and rituximab